SCHEMBL10072718

SCHEMBL10072718

Cc1ccc2c(c1)C(C)(C)c1cc(-c3c4ccccc4c(-c4ccc5ccccc5c4)c4ccncc34)ccc1-2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.37
CYP11B1 P15538 2/20 0.37
CYP11B2 P19099 2/20 0.37
CYP19A1 P11511 1/20 0.37
TDO2 P48775 2/20 0.36
CYP2A6 P11509 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
GSK3B P49841 1/20 0.35
QPCT Q16769 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPK9 P45984 2/20 0.34
MAPK10 P53779 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPK8 P45983 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102676 0.94 CYP11B1 (0.41) CYP17A1CYP11B1CYP11B2CYP19A1TDO2
SCHEMBL1102782 0.93 CYP11B2 (0.43) CYP17A1CYP11B1CYP11B2CYP19A1TDO2
SCHEMBL1105443 0.92 TDO2 (0.35) CYP17A1CYP11B1CYP11B2CYP19A1TDO2
SCHEMBL1103653 0.92 GSK3B (0.36) CYP17A1CYP11B1CYP11B2CYP19A1CYP2A6
SCHEMBL1102725 0.91 CYP11B1 (0.39) CYP17A1CYP11B1CYP11B2CYP19A1TDO2
SCHEMBL1102647 0.91 CYP11B1 (0.42) CYP17A1CYP11B1CYP11B2CYP19A1TDO2
SCHEMBL1104948 0.90 LMNA (0.39) CYP17A1CYP2A6ALDH1A1CYP1A2HPGD
SCHEMBL1104949 0.89 TNF (0.38) TDP1ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL1102625 0.89 TDO2 (0.38) CYP17A1CYP11B1CYP11B2CYP19A1TDO2
SCHEMBL1102655 0.88 CYP11B1 (0.39) CYP17A1CYP11B1CYP11B2CYP19A1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 CYP17A1 2034/4885CYP11B1 836/4885CYP11B2 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.